Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.45 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.44 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.44 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.44 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079189 | 1.00 | PPARA (0.59) | PPARAPPARGGRIK1HDAC3HDAC4 | |
| SCHEMBL10419212 | 0.93 | PPARA (0.52) | PPARAPPARGGRIK1HDAC3HDAC4 | |
| SCHEMBL10420699 | 0.93 | PPARA (0.52) | PPARAPPARGGRIK1HDAC3HDAC4 | |
| SCHEMBL15389812 | 0.89 | GRIK1 (0.53) | PPARAPPARGGRIK1KIF11SLC1A5 | |
| SCHEMBL7036346 | 0.89 | GRIK1 (0.53) | PPARAPPARGGRIK1KIF11SLC1A5 | |
| SCHEMBL15389814 | 0.89 | GRIK1 (0.53) | PPARAPPARGGRIK1KIF11SLC1A5 | |
| SCHEMBL27734651 | 0.86 | PPARG (0.51) | PPARAPPARGGRIK1HDAC3HDAC4 | |
| SCHEMBL27734653 | 0.86 | PPARG (0.51) | PPARAPPARGGRIK1HDAC3HDAC4 | |
| SCHEMBL377574 | 0.84 | GRIK1 (0.73) | PPARAPPARGGRIK1HDAC3HDAC4 | |
| SCHEMBL2130589 | 0.84 | GRIK1 (0.73) | PPARAPPARGGRIK1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | disclosed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | PPARA 448/4885PPARG 250/4885GRIK1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.